receptor (GPCR) GPR35 is involved in oncogenic signaling, bacterial infections, and inflammatory bowel disease transducer interactions and allow for mechanism-based therapies against, for example, inflammatory bowel disease

CCXI), a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases

therapeutic strategies aimed at targeting specific phosphorylation events to modulate G protein signaling in disease our understanding of cellular signaling dynamics and open new avenues for therapeutic intervention in diseases

chemokine receptor system is implicated in a wide range of inflammatory, autoimmune and infectious diseases a single receptor as patients cannot be stratified into CKRs specific subpopulations for a specific disease the majority of potential therapeutic applications are situated in the area of chronic inflammatory disease

UdM”), to discover novel small molecules targeting G-Protein Coupled Receptors (GPCRs) in a metabolic disease

outstanding study on Class B1 GPCRs: insights into multireceptor pharmacology for the treatment of metabolic disease challenges Class B1 GPCRs: insights into multireceptor pharmacology for the treatment of metabolic disease Chemokine CXCL13-CXCR5 signaling in neuroinflammation and pathogenesis of chronic pain and neurological diseases

GPCRs, including β2AR, play key roles in various conditions, such as asthma, cardiovascular diseases, These insights have the potential to advance the treatment of various diseases involving GPCR signalling

D2LR, D3R, and D4R, vasopressin V1AR, and serotonin 5-HT1AR are noted in various neurodegenerative diseases antagonism, kurarinone might be a potential compound that can alleviate clinical symptoms of Parkinson's disease

NETs were also detected in thrombotic lesions in several disease backgrounds, pointing towards a role between platelets and NETs and the potential of this alliance to influence the course of inflammatory diseases

for their work on GPCR gene variants and human genetic disease Ilana Kotliar , Thomas Sakmar , et al. Intelligence Reviews, GPCRs, and more G protein-coupled receptor (GPCR) gene variants and human genetic disease

novel mechanism providing diversity to receptor function and play important roles in physiology and disease

regulation of B2R, which shed light on structure-based drug design for the treatment of B2R-related diseases

fundraising gives us the means to achieve our ambitions: to become a leading player in the field of brain diseases

advanced our understanding of rod outer segment (ROS) morphology and the pathological basis of retinal diseases

for developing therapeutic agents that target specific receptor dimer states to modulate signaling in diseases Perreault, M.L., et al., Heteromeric dopamine receptor signaling complexes: emerging neurobiology and disease

Promising preclinical data supports the applicability of CB2 activation in autoimmune and inflammatory diseases

Promising preclinical data support the applicability of CB2 activation in autoimmune and inflammatory diseases

significance in GPCR internalization dynamics, internalization routes, postinternalization fates, and related diseases

Commercialization of Voyager’s GBA1 Program and Other Next-Generation Gene Therapies for Neurological Diseases Manager Director of Molecular Pharmacology, Discovery Biology Staff Scientist/Senior Staff Scientist, Disease

The levels of chemerin in circulation are correlated with certain disease conditions, such as patients

Heptares and Lilly Enter Multi-target Collaboration and License Agreement in Diabetes and Metabolic Diseases Trial of INV-202, an Oral, Peripherally-acting CB1 Inverse Agonist, in Patients with Diabetic Kidney Disease

focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases

modulator VU0486846 reduces neurogliosis in female Alzheimer's mice The association of GNB5 with Alzheimer disease of GPR139 in the medial septum ameliorates cognitive impairment in two mouse models of Alzheimer's disease

contribute to the implementation of the guidelines, together improving translation from in vitro to disease-relevant

structural approach Mechanisms controlling haemolymph circulation under resting conditions in the chagas disease , and more Class B1 GPCRs: Insights into Multi-Receptor Pharmacology for the Treatment of Metabolic Disease

Although blockade of GPR84 may potentially prove effective also in diseases associated with inflammation

study in Q1 2023 and continue to evaluate the path forward for dipraglurant in a number of interesting disease

pharmacological effects in the treatment of several neurological disorders including, epilepsy, Parkinson’s disease , and Alzheimer’s disease.